An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company Monday announced positive topline results from the Phase 2b ...

Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors ...

Veru (VERU) announced positive topline results from the Phase 2b QUALITY clinical study. The Phase 2b QUALITY clinical study was ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...